U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C18H25NO.BrH.H2O
Molecular Weight 370.324
Optical Activity UNSPECIFIED
Defined Stereocenters 3 / 3
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of DEXTROMETHORPHAN HYDROBROMIDE

SMILES

O.Br.[H][C@]12CCCC[C@]13CCN(C)[C@H]2CC4=CC=C(OC)C=C34

InChI

InChIKey=STTADZBLEUMJRG-IKNOHUQMSA-N
InChI=1S/C18H25NO.BrH.H2O/c1-19-10-9-18-8-4-3-5-15(18)17(19)11-13-6-7-14(20-2)12-16(13)18;;/h6-7,12,15,17H,3-5,8-11H2,1-2H3;1H;1H2/t15-,17+,18+;;/m1../s1

HIDE SMILES / InChI

Molecular Formula H2O
Molecular Weight 18.0153
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula C18H25NO
Molecular Weight 271.3972
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 3 / 3
E/Z Centers 0
Optical Activity UNSPECIFIED

Molecular Formula BrH
Molecular Weight 80.912
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment: Description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/2694543 http://www.who.int/medicines/areas/quality_safety/5.1Dextromethorphan_pre-review.pdf http://www.accessdata.fda.gov/drugsatfda_docs/label/2004/21620_mucinex_lbl.pdf https://www.ncbi.nlm.nih.gov/pubmed/25420446

Dextromethorphan is a non-narcotic morphine derivative widely used as an antitussive for almost 40 years. It has attracted attention due to its anticonvulsant and neuroprotective properties. It is a cough suppressant in many over-the-counter cold and cough medicines. In 2010, the FDA approved the combination product dextromethorphan/quinidine for the treatment of pseudobulbar affect. Dextromethorphan suppresses the cough reflex by a direct action on the cough center in the medulla of the brain. Dextromethorphan shows high-affinity binding to several regions of the brain, including the medullary cough center. This compound is an NMDA receptor antagonist and acts as a non-competitive channel blocker. It is one of the widely used antitussives and is used to study the involvement of glutamate receptors in neurotoxicity. Dextromethorphan (DM) is a sigma-1 receptor agonist and an uncompetitive NMDA receptor antagonist. The mechanism by which dextromethorphan exerts therapeutic effects in patients with pseudobulbar affect is unknown. Dextromethorphan should not be taken with monoamine oxidase inhibitors due to the potential for serotonin syndrome. Dextromethorphan is extensively metabolized by CYP2D6 to dextrorphan, which is rapidly glucuronidated and unable to cross the blood-brain barrier.

Originator

Curator's Comment: # in a Swiss and US patent application from Hoffmann-La Roche in 1946 and 1947, respectively

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
205.0 nM [Ki]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
MUCINEX DM

Approved Use

Helps loosen phlegm (mucus) and thin bronchial secretions to rid the bronchial passageways of bothersome mucus and make coughs more productive: temporarily relieves: cough due to minor throat and bronchial irritation as may occur with the common cold or inhaled irritants; the intensity of coughing; the impulse to cough to help you get to sleep

Launch Date

2004
Primary
NUEDEXTA

Approved Use

NUEDEXTA is indicated for the treatment of pseudobulbar affect (PBA). PBA occurs secondary to a variety of otherwise unrelated neurologic conditions, and is characterized by involuntary, sudden, and frequent episodes of laughing and/or crying. PBA episodes typically occur out of proportion or incongruent to the underlying emotional state. PBA is a specific condition, distinct from other types of emotional lability that may occur in patients with neurological disease or injury.

Launch Date

2010
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
4.2 ng/mL
45 mg 2 times / day steady-state, oral
dose: 45 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
DEXTROMETHORPHAN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
7.7 ng/mL
60 mg 2 times / day steady-state, oral
dose: 60 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
DEXTROMETHORPHAN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
95.5 ng/mL
30 mg 2 times / day steady-state, oral
dose: 30 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered: QUINIDINE
DEXTROMETHORPHAN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
15.9 ng/mL
30 mg single, oral
dose: 30 mg
route of administration: Oral
experiment type: SINGLE
co-administered: QUINIDINE
DEXTROMETHORPHAN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
2.9 ng/mL
30 mg 2 times / day steady-state, oral
dose: 30 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
DEXTROMETHORPHAN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
123.5 ng/mL
30 mg 2 times / day steady-state, oral
dose: 30 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered: QUINIDINE
DEXTRORPHAN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
124.9 ng/mL
30 mg single, oral
dose: 30 mg
route of administration: Oral
experiment type: SINGLE
co-administered: QUINIDINE
DEXTRORPHAN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
599 ng/mL
45 mg 2 times / day steady-state, oral
dose: 45 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
DEXTRORPHAN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
709 ng/mL
60 mg 2 times / day steady-state, oral
dose: 60 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
DEXTRORPHAN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
32 ng × h/mL
45 mg 2 times / day steady-state, oral
dose: 45 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
DEXTROMETHORPHAN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
52 ng × h/mL
60 mg 2 times / day steady-state, oral
dose: 60 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
DEXTROMETHORPHAN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
1049 ng × h/mL
30 mg 2 times / day steady-state, oral
dose: 30 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered: QUINIDINE
DEXTROMETHORPHAN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
133.3 ng × h/mL
30 mg single, oral
dose: 30 mg
route of administration: Oral
experiment type: SINGLE
co-administered: QUINIDINE
DEXTROMETHORPHAN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
17.8 ng × h/mL
30 mg 2 times / day steady-state, oral
dose: 30 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
DEXTROMETHORPHAN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
1000.5 ng × h/mL
30 mg 2 times / day steady-state, oral
dose: 30 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered: QUINIDINE
DEXTRORPHAN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
933.8 ng × h/mL
30 mg single, oral
dose: 30 mg
route of administration: Oral
experiment type: SINGLE
co-administered: QUINIDINE
DEXTRORPHAN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
2898 ng × h/mL
45 mg 2 times / day steady-state, oral
dose: 45 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
DEXTRORPHAN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
3608 ng × h/mL
60 mg 2 times / day steady-state, oral
dose: 60 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
DEXTRORPHAN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
68 nM*h
30 mg single, oral
dose: 30 mg
route of administration: oral
experiment type: single
co-administered:
DEXTROMETHORPHAN plasma
Homo sapiens
population: healthy
age: adults
sex:
food status:
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
13.1 h
30 mg 2 times / day steady-state, oral
dose: 30 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered: QUINIDINE
DEXTROMETHORPHAN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
50 mg 4 times / day steady, oral
Dose: 50 mg, 4 times / day
Route: oral
Route: steady
Dose: 50 mg, 4 times / day
Sources:
unhealthy, 19-52 years
n = 16
Health Status: unhealthy
Condition: chronic intractable partial onset seizures
Age Group: 19-52 years
Sex: M+F
Population Size: 16
Sources:
960 mg 1 times / day multiple, oral
Highest studied dose
Dose: 960 mg, 1 times / day
Route: oral
Route: multiple
Dose: 960 mg, 1 times / day
Sources:
unhealthy, 19-67 years
n = 11
Health Status: unhealthy
Condition: Huntington's disease
Age Group: 19-67 years
Sex: M+F
Population Size: 11
Sources:
120 mg single, oral
Recommended
Dose: 120 mg
Route: oral
Route: single
Dose: 120 mg
Sources:
healthy, 26.5 years
n = 40
Health Status: healthy
Age Group: 26.5 years
Sex: M+F
Population Size: 40
Sources:
900 mg single, oral
Overdose
Dose: 900 mg
Route: oral
Route: single
Dose: 900 mg
Sources:
unknown, 27 years
n = 1
Health Status: unknown
Age Group: 27 years
Sex: M
Population Size: 1
Sources:
Other AEs: Ischemic colitis...
Other AEs:
Ischemic colitis (1 patient)
Sources:
270 mg single, oral
Overdose
Dose: 270 mg
Route: oral
Route: single
Dose: 270 mg
Sources:
unknown, 3 years
n = 1
Health Status: unknown
Age Group: 3 years
Sex: M
Population Size: 1
Sources:
Other AEs: Lethargy, Ataxia...
Other AEs:
Lethargy (1 patient)
Ataxia (1 patient)
Nystagmus (1 patient)
Sources:
AEs

AEs

AESignificanceDosePopulation
Ischemic colitis 1 patient
900 mg single, oral
Overdose
Dose: 900 mg
Route: oral
Route: single
Dose: 900 mg
Sources:
unknown, 27 years
n = 1
Health Status: unknown
Age Group: 27 years
Sex: M
Population Size: 1
Sources:
Ataxia 1 patient
270 mg single, oral
Overdose
Dose: 270 mg
Route: oral
Route: single
Dose: 270 mg
Sources:
unknown, 3 years
n = 1
Health Status: unknown
Age Group: 3 years
Sex: M
Population Size: 1
Sources:
Lethargy 1 patient
270 mg single, oral
Overdose
Dose: 270 mg
Route: oral
Route: single
Dose: 270 mg
Sources:
unknown, 3 years
n = 1
Health Status: unknown
Age Group: 3 years
Sex: M
Population Size: 1
Sources:
Nystagmus 1 patient
270 mg single, oral
Overdose
Dose: 270 mg
Route: oral
Route: single
Dose: 270 mg
Sources:
unknown, 3 years
n = 1
Health Status: unknown
Age Group: 3 years
Sex: M
Population Size: 1
Sources:
Overview

OverviewOther

Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
no
no
no
no
no
no
no
no
no
no
no
no
Drug as victimTox targets

Tox targets

TargetModalityActivityMetaboliteClinical evidence
PubMed

PubMed

TitleDatePubMed
The need for rational therapeutics in the use of cough and cold medicine in infants.
1992 Apr
Cytochrome P450 2D6.1 and cytochrome P450 2D6.10 differ in catalytic activity for multiple substrates.
2001 Aug
Prediction models in the design of neural network based ECG classifiers: a neural network and genetic programming approach.
2002
A sensitive LC-MS/MS assay for the determination of dextromethorphan and metabolites in human urine--application for drug interaction studies assessing potential CYP3A and CYP2D6 inhibition.
2002 Aug 22
Consultation with the specialist: the central serotonin syndrome: paradigm for psychotherapeutic misadventure.
2002 Dec
Expression, purification, biochemical characterization, and comparative function of human cytochrome P450 2D6.1, 2D6.2, 2D6.10, and 2D6.17 allelic isoforms.
2002 Dec
The African-specific CYP2D617 allele encodes an enzyme with changed substrate specificity.
2002 Jan
Dextromethorphan is effective in the treatment of subacute methotrexate neurotoxicity.
2002 Jul-Aug
Substrate specificity for rat cytochrome P450 (CYP) isoforms: screening with cDNA-expressed systems of the rat.
2002 Mar 1
Broad substrate specificity of human cytochrome P450 46A1 which initiates cholesterol degradation in the brain.
2003 Dec 9
Non-competitive NMDA receptor antagonists moderate seizure-induced c-fos expression in the rat cerebral cortex.
2003 Feb 15
Combined phenotypic assessment of cytochrome p450 1A2, 2C9, 2C19, 2D6, and 3A, N-acetyltransferase-2, and xanthine oxidase activities with the "Cooperstown 5+1 cocktail".
2003 Nov
Analysis of pharmacokinetic parameters for assessment of dextromethorphan metabolic phenotypes.
2003 Sep-Oct
Evidence of significant contribution from CYP3A5 to hepatic drug metabolism.
2004 Dec
Comparison of various urine collection intervals for caffeine and dextromethorphan phenotyping in children.
2004 Jul
Evaluation of the One-Step ELISA kit for the detection of buprenorphine in urine, blood, and hair specimens.
2004 Jul 16
Potential of pranlukast and zafirlukast in the inhibition of human liver cytochrome P450 enzymes.
2004 May
Dimemorfan prevents seizures induced by the L-type calcium channel activator BAY k-8644 in mice.
2004 May 5
Bladder emptying over a period of 10-45 years after a traumatic spinal cord injury.
2004 Nov
Evaluation of fresh and cryopreserved hepatocytes as in vitro drug metabolism tools for the prediction of metabolic clearance.
2004 Nov
Treatment of pseudobulbar affect in ALS with dextromethorphan/quinidine: a randomized trial.
2004 Oct 26
[Dextromethorphan enhances analgesic activity of propacetamol--experimental study].
2005
Phenotypical expression of CYP2D6 in amerindians of tepehuano origin from Durango, Mexico.
2005
The dextromethorphan analog dimemorfan attenuates kainate-induced seizures via sigma1 receptor activation: comparison with the effects of dextromethorphan.
2005 Apr
Characterization of microsomal cytochrome P450-dependent monooxygenases in the rat olfactory mucosa.
2005 Aug
Multiple P450 substrates in a single run: rapid and comprehensive in vitro interaction assay.
2005 Jan
MK-801 and dextromethorphan block microglial activation and protect against methamphetamine-induced neurotoxicity.
2005 Jul 19
Evaluation of dextromethorphan metabolism using hepatocytes from CYP2D6 poor and extensive metabolizers.
2005 Jun
Cytochrome P450 2D6 (CYP2D6) inhibitory constituents of Catharanthus roseus.
2005 Jun
Recombinant production of human microsomal cytochrome P450 2D6 in the methylotrophic yeast Pichia pastoris.
2005 Nov
Bench-to-bedside review: mechanisms and management of hyperthermia due to toxicity.
2007
Immunohistological assessment of the synovial tissue in small joints in rheumatoid arthritis: validation of a minimally invasive ultrasound-guided synovial biopsy procedure.
2007
Sex differences in the potency of kappa opioids and mixed-action opioids administered systemically and at the site of inflammation against capsaicin-induced hyperalgesia in rats.
2007 Apr
Treatment of the common cold.
2007 Feb 15
Free energies of binding of R- and S-propranolol to wild-type and F483A mutant cytochrome P450 2D6 from molecular dynamics simulations.
2007 Jul
Validated method for rapid inhibition screening of six cytochrome P450 enzymes by liquid chromatography-tandem mass spectrometry.
2007 Jun 1
Prior exposure to uninfected mosquitoes enhances mortality in naturally-transmitted West Nile virus infection.
2007 Nov 14
Ubiquitous computing for remote cardiac patient monitoring: a survey.
2008
Mechanical aspects of a multidirectional, angular stable osteosynthesis system and comparison with four conventional systems.
2008 Apr
Sex differences in NMDA antagonist enhancement of morphine antihyperalgesia in a capsaicin model of persistent pain: comparisons to two models of acute pain.
2008 Apr
Sigma ligands, but not N-methyl-D-aspartate antagonists, reduce levodopa-induced dyskinesias.
2008 Jan 8
Anti-inflammatory effects of dimemorfan on inflammatory cells and LPS-induced endotoxin shock in mice.
2008 Jul
Life-threatening dextromethorphan intoxication associated with interaction with amitriptyline in a poor CYP2D6 metabolizer: a single case re-exposure study.
2008 Jul
Effects of repeated cycles of sterilisation on the mechanical characteristics of titanium miniplates for osteosynthesis.
2008 Sep
Effect of fenofibrate on microcirculation and wound healing in healthy and diabetic mice.
2009
The diagnostic role of glycosaminoglycans in pleural effusions: a pilot study.
2009 Feb 18
Amyotrophic lateral sclerosis.
2009 Feb 3
Riluzole treatment, survival and diagnostic criteria in Parkinson plus disorders: the NNIPPS study.
2009 Jan
Retrospective analysis of titanium plate-retained prostheses placed after total rhinectomy.
2009 Jan-Feb
[Bone anchored hearing aids (BAHA)].
2009 Mar
Patents

Sample Use Guides

In Vivo Use Guide
Curator's Comment: https://www.ncbi.nlm.nih.gov/pubmed/1503667 https://www.ncbi.nlm.nih.gov/pubmed/26000221
15-30 mg 3 to 4 times per day (cough) 20-30 mg twice daily (pseudobulbar affect)
Route of Administration: Oral
In vitro studies pre- and immature oligodendroglial (OLN-93) cells were subjected to hyperoxic conditions for 48 h after pre-treatment with increasing doses of dextromethorphan.
Substance Class Chemical
Created
by admin
on Fri Dec 15 15:04:42 GMT 2023
Edited
by admin
on Fri Dec 15 15:04:42 GMT 2023
Record UNII
9D2RTI9KYH
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
DEXTROMETHORPHAN HYDROBROMIDE
EP   ORANGE BOOK   USP   USP-RS   VANDF   WHO-IP  
Common Name English
DEXTROMETHORPHAN HYDROBROMIDE COMPONENT OF MUCINEX DM
Common Name English
DEXTROMETHORPHAN HYDROBROMIDE COMPONENT OF NUEDEXTA
Common Name English
BROMFED-DM COMPONENT DEXTROMETHORPHAN HYDROBROMIDE
Common Name English
DEXTROMETHORPHAN HYDROBROMIDE [USP-RS]
Common Name English
ST. JOSEPH COUGH SYRUP
Brand Name English
AZEDIPAMIN
Common Name English
AUVELITY COMPONENT DEXTROMETHORPHAN HYDROBROMIDE
Brand Name English
DEXTROMETHORPHAN HYDROBROMIDE COMPONENT OF BROMANATE DM
Common Name English
DEXTROMETHORPHAN HYDROBROMIDE HYDRATE [JAN]
Common Name English
BROMANATE DM COMPONENT DEXTROMETHORPHAN HYDROBROMIDE
Common Name English
DEXTROMETHORPHAN HYDROBROMIDE COMPONENT OF PHERAZINE DM
Common Name English
DIMETANE-DX COMPONENT DEXTROMETHORPHAN HYDROBROMIDE
Common Name English
DEXTROMETHORPHAN HYDROBROMIDE HYDRATE
JAN  
Common Name English
AVP-923 COMPONENT DEXTROMETHORPHAN HYDROBROMIDE
Common Name English
DEXTROMETHORPHAN HYDROBROMIDE [EP MONOGRAPH]
Common Name English
DEXTROMETHORPHAN HYDROBROMIDE COMPONENT OF AUVELITY
Brand Name English
DEXTROMETHORPHAN HYDROBROMIDE [WHO-IP]
Common Name English
DEXTROMETHORPHAN HYDROBROMIDE MONOHYDRATE
WHO-DD  
Common Name English
3-METHOXY-17-METHYL-9.ALPHA.,13.ALPHA.,14.ALPHA.-MORPHINAN HBR MONOHYDRATE
Common Name English
MORPHINAN, 3-METHOXY-17-METHYL-, (9.ALPHA.,13.ALPHA.,14.ALPHA.)-, HBR, MONOHYDRATE
Common Name English
DEXTROMETHORPHAN HYDROBROMIDE COMPONENT OF BROMFED-DM
Common Name English
DEXTROMETHORPHAN HYDROBROMIDE COMPONENT OF DIMETANE-DX
Common Name English
MORPHINAN, 3-METHOXY-17-METHYL-, (9.ALPHA.,13.ALPHA.,14.ALPHA.)-, HYDROBROMIDE, MONOHYDRATE
Common Name English
CALMOCITENE
Common Name English
DRIXORAL COUGH
Common Name English
DEXTROMETHORPHANI HYDROBROMIDUM [WHO-IP]
Common Name English
SIMASEDAN
Common Name English
DEXTROMETHORPHAN HYDROBROMIDE OROS TABLETS
Common Name English
DEXTROMETHORPHAN HBR
Common Name English
MUCINEX DM COMPONENT DEXTROMETHORPHAN HYDROBROMIDE
Common Name English
DEXTROMETHORPHAN HYDROBROMIDE COMPONENT OF PROMETHAZINE DM
Common Name English
NUEDEXTA COMPONENT DEXTROMETHORPHAN HYDROBROMIDE
Common Name English
DEXTROMETHORPHAN HYDROBROMIDE [ORANGE BOOK]
Common Name English
BENYLIN DM
Common Name English
Dextromethorphan hydrobromide monohydrate [WHO-DD]
Common Name English
3-Methoxy-17-methyl-9α,13α,14α-morphinan hydrobromide monohydrate
Common Name English
DEXTROMETHORPHAN HYDROBROMIDE [VANDF]
Common Name English
PROMETHAZINE DM COMPONENT DEXTROMETHORPHAN HYDROBROMIDE
Common Name English
NUEDEXTA
Brand Name English
DEXTROMETHORPHAN HYDROBROMIDE [USP MONOGRAPH]
Common Name English
ROMILAR
Common Name English
PEDIACARE 1
Common Name English
PHERAZINE DM COMPONENT DEXTROMETHORPHAN HYDROBROMIDE
Common Name English
Classification Tree Code System Code
CFR 21 CFR 341.14
Created by admin on Fri Dec 15 15:04:42 GMT 2023 , Edited by admin on Fri Dec 15 15:04:42 GMT 2023
FDA ORPHAN DRUG 556716
Created by admin on Fri Dec 15 15:04:42 GMT 2023 , Edited by admin on Fri Dec 15 15:04:42 GMT 2023
NCI_THESAURUS C67413
Created by admin on Fri Dec 15 15:04:42 GMT 2023 , Edited by admin on Fri Dec 15 15:04:42 GMT 2023
EMA ASSESSMENT REPORTS NUEDEXTA (AUTHORIZED: NEUROBEHAVIORAL MANIFESTATIONS)
Created by admin on Fri Dec 15 15:04:42 GMT 2023 , Edited by admin on Fri Dec 15 15:04:42 GMT 2023
NCI_THESAURUS C1506
Created by admin on Fri Dec 15 15:04:42 GMT 2023 , Edited by admin on Fri Dec 15 15:04:42 GMT 2023
CFR 21 CFR 341.74
Created by admin on Fri Dec 15 15:04:42 GMT 2023 , Edited by admin on Fri Dec 15 15:04:42 GMT 2023
Code System Code Type Description
CHEBI
4470
Created by admin on Fri Dec 15 15:04:42 GMT 2023 , Edited by admin on Fri Dec 15 15:04:42 GMT 2023
PRIMARY
DAILYMED
9D2RTI9KYH
Created by admin on Fri Dec 15 15:04:42 GMT 2023 , Edited by admin on Fri Dec 15 15:04:42 GMT 2023
PRIMARY
DRUG BANK
DBSALT000376
Created by admin on Fri Dec 15 15:04:42 GMT 2023 , Edited by admin on Fri Dec 15 15:04:42 GMT 2023
PRIMARY
WHO INTERNATIONAL PHARMACOPEIA
DEXTROMETHORPHAN HYDROBROMIDE
Created by admin on Fri Dec 15 15:04:42 GMT 2023 , Edited by admin on Fri Dec 15 15:04:42 GMT 2023
PRIMARY Description: A white or almost white, crystalline powder.Solubility: Sparingly soluble in water; freely soluble in ethanol (~750 g/L) TS.Category: Antitussive.Storage: Dextromethorphan hydrobromide should be kept in a well-closed container.
RXCUI
102490
Created by admin on Fri Dec 15 15:04:42 GMT 2023 , Edited by admin on Fri Dec 15 15:04:42 GMT 2023
PRIMARY RxNorm
RS_ITEM_NUM
1181007
Created by admin on Fri Dec 15 15:04:42 GMT 2023 , Edited by admin on Fri Dec 15 15:04:42 GMT 2023
PRIMARY
FDA UNII
9D2RTI9KYH
Created by admin on Fri Dec 15 15:04:42 GMT 2023 , Edited by admin on Fri Dec 15 15:04:42 GMT 2023
PRIMARY
EVMPD
SUB01645MIG
Created by admin on Fri Dec 15 15:04:42 GMT 2023 , Edited by admin on Fri Dec 15 15:04:42 GMT 2023
PRIMARY
ChEMBL
CHEMBL52440
Created by admin on Fri Dec 15 15:04:42 GMT 2023 , Edited by admin on Fri Dec 15 15:04:42 GMT 2023
PRIMARY
NCI_THESAURUS
C423
Created by admin on Fri Dec 15 15:04:42 GMT 2023 , Edited by admin on Fri Dec 15 15:04:42 GMT 2023
PRIMARY
EVMPD
SUB27099
Created by admin on Fri Dec 15 15:04:42 GMT 2023 , Edited by admin on Fri Dec 15 15:04:42 GMT 2023
PRIMARY
WIKIPEDIA
Dextromethorphan hydrobromide
Created by admin on Fri Dec 15 15:04:42 GMT 2023 , Edited by admin on Fri Dec 15 15:04:42 GMT 2023
PRIMARY
EPA CompTox
DTXSID8045569
Created by admin on Fri Dec 15 15:04:42 GMT 2023 , Edited by admin on Fri Dec 15 15:04:42 GMT 2023
PRIMARY
CAS
6700-34-1
Created by admin on Fri Dec 15 15:04:42 GMT 2023 , Edited by admin on Fri Dec 15 15:04:42 GMT 2023
PRIMARY
PUBCHEM
5462351
Created by admin on Fri Dec 15 15:04:42 GMT 2023 , Edited by admin on Fri Dec 15 15:04:42 GMT 2023
PRIMARY
CHEBI
4471
Created by admin on Fri Dec 15 15:04:42 GMT 2023 , Edited by admin on Fri Dec 15 15:04:42 GMT 2023
PRIMARY
Related Record Type Details
PARENT -> SALT/SOLVATE
BASIS OF STRENGTH->SUBSTANCE
ASSAY (TITRATION)
EP
ANHYDROUS->SOLVATE
BASIS OF STRENGTH->SUBSTANCE
ASSAY (HPLC)
USP
Related Record Type Details
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
and not more than 1 such peak has an area greater than 0.5 times the area of the principal peak in the chromatogram obtained with reference solution (b) (0.25 per cent)
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
IMPURITY -> PARENT
and not more than 1 such peak has an area greater than 0.5 times the area of the principal peak in the chromatogram obtained with reference solution (b) (0.25 per cent); For the calculation of contents, multiply the peak areas by 0.2
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
Related Record Type Details
ACTIVE MOIETY